Department of Hematology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Metallomics. 2020 Mar 1;12(3):326-336. doi: 10.1039/c9mt00308h. Epub 2020 Mar 12.
Arsenic trioxide (ATO) has been recognized as a drug for the treatment of various diseases in traditional medicine for more than two thousand years. Although ATO has recently shown excellent efficacy for the treatment of acute promyelocytic leukemia (APL), it could not provide satisfactory outcomes as a single-agent for the management of non-APL leukemia or different solid tumors. Nevertheless, combination treatment strategies, e.g., ATO with other agents, have shown promising results against different diseases. Here, we introduce in depth the latest evidence and detailed insights into ATO-mediated cures for APL by targeting PML/RARα chimeric protein, followed by the preclinical and clinical efficacy of ATO on various non-APL malignancies and solid tumors. Likewise, the antiviral activity of ATO against human immunodeficiency virus (HIV) and hepatitis C virus (HCV) was also discussed briefly. Our review would provide a clear prospect for the combination of ATO with other agents for treatment of numerous neoplastic diseases, and open a new era in the clinically applicable range of arsenicals.
三氧化二砷（ATO）作为一种药物在传统医学中已经被用于治疗多种疾病超过两千年了。尽管 ATO 最近在治疗急性早幼粒细胞白血病（APL）方面表现出了极好的疗效，但作为单一药物用于治疗非 APL 白血病或不同实体瘤的效果并不理想。然而，联合治疗策略，例如 ATO 与其他药物联合使用，在治疗不同疾病方面已经显示出了很有前景的结果。在这里，我们深入介绍了 ATO 通过靶向 PML/RARα嵌合蛋白治疗 APL 的最新证据和详细见解，随后介绍了 ATO 在各种非 APL 恶性肿瘤和实体瘤方面的临床前和临床疗效。同样，我们也简要讨论了 ATO 对人类免疫缺陷病毒（HIV）和丙型肝炎病毒（HCV）的抗病毒活性。我们的综述为 ATO 与其他药物联合治疗多种肿瘤疾病提供了明确的前景，并为砷剂的临床应用范围开辟了一个新时代。
